Conmed vs Integer
CNMD and ITGR side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CNMD and ITGR compare
Integer is the larger company, worth 2.8 times as much as Conmed ($4.3B against $1.5B).
On earnings, Conmed is cheaper: it trades at 21.0× trailing earnings, against 42.5× for Integer.
Conmed grew revenue faster over the last twelve months (1.6% versus −0.31% for Integer).
Integer keeps more of each dollar of sales as profit, with a net margin of 5.7% compared with 5.4% at Conmed.
Conmed scores higher on the StockData Score (14 against 8 for Integer), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CNMD | ITGR |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $4.3B |
| Share price | $50.77 | $126.68 |
| Change, 1 year | 15.5% | 84.2% |
| Change, 5 years | −64.2% | 41.2% |
| Beta (5Y) | 0.94 | 0.78 |
| Employees | 3,900 | 11K |
| StockData Score | ||
| Total score | 14 (better) | 8 |
| Valuation score | 6 (better) | 1 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 3 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 21.0× (better) | 42.5× |
| P/S | 1.1× (better) | 2.4× |
| P/B | 1.4× (better) | 2.5× |
| EV/EBITDA | 16.8× (better) | 19.0× |
| P/FCF | 11.4× (better) | 52.6× |
| PEG | – | 3.21 |
| FCF yield | 8.8% (better) | 1.9% |
| Fair value | $67.18 | $103.47 |
| Margin of safety | 24.4% (better) | −22.4% |
| Growth | ||
| Revenue growth (TTM) | 1.6% (better) | −0.31% |
| Revenue growth, 5Y average | 9.8% | 11.5% (better) |
| Net income growth (TTM) | 14.6% | 19.3% (better) |
| EPS growth (TTM) | 18.0% | 24.7% (better) |
| EPS growth, 5Y average | 36.4% (better) | 4.4% |
| Profitability | ||
| Gross margin | 57.6% (better) | 24.6% |
| Operating margin | 9.9% (better) | 8.2% |
| Net margin | 5.4% | 5.7% (better) |
| FCF margin | 9.7% (better) | 4.5% |
| Return on equity | 7.1% (better) | 6.0% |
| Return on invested capital | 5.2% (better) | 5.0% |
| Financial health | ||
| Debt / equity | 0.77 | 0.71 (better) |
| Net debt / EBITDA | 5.66 | 4.16 (better) |
| Interest coverage | 4.1× (better) | 3.9× |
| Current ratio | 1.49 | 3.98 (better) |
| Altman Z-score | 2.03 | 2.88 (better) |
| Piotroski F-score | 6 | 7 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Payout ratio | 8.4% | – |
| Years of dividend growth | 0 | – |
| Dividend growth, 5Y average | −5.6% | – |
| Buyback yield | – | 2.3% |
| Shareholder yield | 0.00% | 2.3% (better) |
| Ownership | ||
| Held by institutions | 114% | 120% |
| Held by insiders | 0.47% | 15.1% |
| Insider net buying, 12 months | $0 (better) | −$5.2M |
| Short interest, % of float | 6.3% | 11.9% |
Go deeper
- CNMD stock overview
- CNMD income statement
- CNMD valuation and score
- ITGR stock overview
- ITGR income statement
- ITGR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.